$CHMA News

Last published 4y ago

4y agoAMYT CHMAAmryt Reports Q3 2022 Financial and Operational ResultsGlobeNewswireAmryt Reports Q3 2022 Financial and Operational Results 8.2% YoY revenue growth in Q3 to $61.1M - 12.5% on a constant currency basis 11th consecutive quarter of positive EBITDA generation; $12.5M in Q3 2022 Operating
4y agoAMYT CHMAAmryt Reports Record Q2 2022 ResultsGlobeNewswireAmryt Reports Record Q2 2022 Results 9.2% YoY revenue growth in Q2 to $68.5M 35.3% YoY revenue growth in Q2 excluding impact of a sporadic LATAM order in Q2 2021 7.8% growth in metreleptin revenues YoY to $46.4M in Q2 49.9% growth in
4y agoCHMA NRSNSpyBiotech Appoints Seasoned Biotech Executive Mark Leuchtenberger as Chief Executive OfficerBusiness WireNovel Vaccine Company Expands Leadership Team and Establishes US Presence SpyBiotech, a British biotechnology company with a novel vaccine platform technology that can target infectious diseases, cancer, and chronic diseases, has appointed Mark Leuch
4y agoAMYT CHMAAmryt Reports Record Q1 2022 ResultsGlobeNewswireAmryt Reports Record Q1 2022 Results CHMP adopts positive opinion for Filsuvez® for the treatment of Dystrophic and Junctional EB Reaffirming FY 2022 revenue guidance to $260M - $270M, representing 17-21% YoY growth Board approved stock repurc
4y agoAMYT CHMAAmryt Announces 22% growth in FY 2021 Revenues to $222.5MGlobeNewswireAmryt Announces 22% growth in FY 2021 Revenues to $222.5M Issuing FY 2022 revenue guidance of $260M - $270M, representing 17%-21% YoY growth Cash of $113.0M at December 31, 2021 Board approves stock repurchase program of up to $30M 8th con
5y agoCHMA PULMPulmatrix appoints Director Anand VaradanPR NewswireLEXINGTON, Mass., July 27, 2021 /PRNewswire/ -- Pulmatrix, Inc. (NASDAQ: PULM), a clinical-stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary and non-pulmonary disease using its patented iSPERSE™ tec
5y agoCHMAChiasma Announces Submission of Marketing Authorization Application for MYCAPSSA® to the European Medicines AgencyGlobeNewswireNEEDHAM, Mass., June 28, 2021 (GLOBE NEWSWIRE) -- Chiasma, Inc. (NASDAQ:CHMA), ("Chiasma" or the "Company"), a commercial-stage biopharmaceutical company utilizing its delivery platform technology to develop and commercialize oral therapies to improve
5y agoAMYT CHMAAmryt Pharma Announces Filing of Preliminary Registration Statement on Form F-4 in Connection with Its Proposed Acquisition of Chiasma, Inc.GlobeNewswireAmryt Pharma Announces Filing of Preliminary Registration Statement on Form F-4 in Connection with Its Proposed Acquisition of Chiasma, Inc. DUBLIN, Ireland, and Boston MA, June 15, 2021, Amryt (NASDAQ:AMYT, AIM: AMYT))), a global, commercial-stage
5y agoCHMAChiasma Presents Positive Patient-Reported Outcomes Data from its MPOWERED™ Phase 3 Trial Comparing MYCAPSSA® to Long-Acting Injectables for the Maintenance Treatment of Adults with AcromegalyGlobeNewswireNEEDHAM, Mass., May 27, 2021 (GLOBE NEWSWIRE) -- Chiasma, Inc. (NASDAQ:CHMA), ("Chiasma" or the "Company") today presented patient-reported outcomes (PROs) data from its MPOWERED™ Phase 3 trial demonstrating that study patients with acromegaly report
5y agoCHMAChiasma to Present Encore and New Data from MPOWERED™ Phase 3 Trial at Upcoming e-ECE and AACE Virtual ConferencesGlobeNewswire-- New clinical data accepted for oral and e-Poster presentation at AACE -- -- e-ECE clinical data previously presented at Endocrine Society's 2021 annual meeting -- NEEDHAM, Mass., May 20, 2021 (GLOBE NEWSWIRE) -- Chiasma, Inc. (NASDAQ:C
5y agoCHMAAcentrus Specialty Contracts with Chiasma to Bring MYCAPSSA® (octreotide) to Health Systems and Hospitals in the Acentrus NetworkBusiness WireAcentrus Specialty™, a national network of health systems and hospitals committed to providing specialty pharmacy care for their patients, has finalized an agreement with Chiasma, Inc. (NASDAQ:CHMA) to provide qualified Acentrus clients access to MYCA
5y agoCHMA HOME MDP MSGNMoore Kuehn Encourages MSGN, HOME, CHMA and MDP Investors to Contact Law FirmPR NewswireNEW YORK, May 11, 2021 /PRNewswire/ -- Moore Kuehn, PLLC, a law firm focusing in securities litigation located on Wall Street in downtown New York City, is investigating potential claims concerning whether the following proposed mergers are fair to shar
5y agoCHMAChiasma, Inc. to Host Earnings CallACCESS NewswireNEW YORK, NY / ACCESSWIRE / May 6, 2021 / Chiasma, Inc. (NASDAQ:CHMA) will be discussing their earnings results in their 2021 First Quarter Earnings call to be held on May 6, 2021 at 5:00 PM Eastern Time. To listen to the event live or access a replay o
5y agoATNX BLRX CHMA IBIO+1Thinking about buying stock in Chiasma, Athenex, iBio, BioLineRx, or Endra Life Sciences?PR NewswireNEW YORK, May 5, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for CHMA, ATNX, IBIO, BLRX, and NDRA. To
5y agoAMYT CHMAAmryt Reports Record Q1 2021 Financial and Operating ResultsGlobeNewswireAmryt Reports Record Q1 2021 Financial and Operating Results 8.7% YoY revenue growth in the quarter to $48.4M 16.5% YoY underlying revenue growth excluding the impact of a LATAM periodic order in Q1 2020 5th consecutive quarter of positive EBIT
5y agoCHMAChiasma Reports First Quarter Financial Results and Announced Agreement to Merge with AmrytGlobeNewswireAnnounced agreement to merge with Amryt Combination to create a global commercial stage rare and orphan disease leader with a diversified portfolio of therapies and a meaningful late-stage development pipeline Q1 2021 Net Product Revenues of $1
5y agoAMYT CHMAAmryt Pharma to Acquire Chiasma, Inc. to Further Strengthen Global Leadership in Rare and Orphan DiseasesGlobeNewswire- Combined business will have three approved commercial products, lomitapide (Lojuxta®/Juxtapid®), metreleptin (Myalept®/ Myalepta®), octreotide (MYCAPSSA®) and a robust clinical pipeline - Lead pipeline product Oleogel-S10*(Filsuvez®) under r
5y agoCHMAChiasma to Report First Quarter Financial Results on May 6, 2021GlobeNewswireNEEDHAM, Mass., April 29, 2021 (GLOBE NEWSWIRE) -- Chiasma, Inc. (NASDAQ:CHMA), a commercial stage biopharmaceutical company, today announced that it will host a live conference call and audio webcast on Thursday, May 6, 2021 at 5:00 pm Eastern Time
5y agoCHMAChiasma Presents Long-Term Safety and Efficacy Data from the Open-Label Extension Study of its CHIASMA OPTIMAL Phase 3 Trial Evaluating MYCAPSSA® in Patients with Acromegaly at ENDO 2021GlobeNewswire--93% of all patients who enrolled as a responder to MYCAPSSA® maintained their biochemical response at the end of the 48-week open-label extension (OLE) period-- --Safety profile during the OLE was...
5y agoCHMAChiasma Presents New Positive Data for MYCAPSSA from Phase 3 Trial MPOWERED™ for the Maintenance Treatment of Acromegaly at ENDO 2021GlobeNewswire--Data supports MYCAPSSA® as non-inferior to long-acting injectable somatostatin receptor ligands (iSRLs)-- --Data demonstrated patients taking MYCAPSSA had significant improvement in acromegaly...
5y agoCHMAChiasma to Present New Data from Two Phase 3 Trials, CHIASMA OPTIMAL and MPOWERED™, at ENDO 2021GlobeNewswire-- One oral presentation and five late-breaking posters accepted -- NEEDHAM, Mass., March 10, 2021 (GLOBE NEWSWIRE) -- Chiasma, Inc. (NASDAQ: CHMA), (“Chiasma” or the “Company”), a commercial-stage...
5y agoCHMAChiasma (CHMA) Q4 2020 Earnings Call TranscriptEarnings Call TranscriptsCHMA earnings call for the period ending December 31, 2020.
5y agoCHMAChiasma Reports Fourth Quarter and Full-Year 2020 Financial Results and Provides Corporate UpdateGlobeNewswirePhased launch of MYCAPSSA® progressing with 2020 net product revenue of $1.1 million Achieved payor coverage of MYCAPSSA for over 150 million lives Company to host conference call today, March 4,...
5y agoCHMAChiasma to Report Fourth Quarter 2020 Results on March 4GlobeNewswireNEEDHAM, Maine, Feb. 25, 2021 (GLOBE NEWSWIRE) -- Chiasma, Inc. (NASDAQ: CHMA), a commercial stage biopharmaceutical company, today announced that it will host a conference call and live audio...
5y agoCHMAChiasma Announces Hiring of John Doyle as Chief Financial OfficerGlobeNewswireNEEDHAM, Mass., Jan. 19, 2021 (GLOBE NEWSWIRE) -- Chiasma, Inc. (NASDAQ: CHMA), a commercial-stage biopharmaceutical company utilizing its delivery platform technology to develop and commercialize...
5y agoCHMAChiasma Provides Corporate Update and Previews Expected 2021 MilestonesGlobeNewswireMYCAPSSA® launch in US continuing to gain traction with physicians, patients, and payers MYCAPSSA® EMA submission for EU marketing approval on track for mid-2021 following positive results of...
5y agoCHMAChiasma to Participate in Two Investor Conferences in DecemberGlobeNewswireNEEDHAM, Mass., Nov. 23, 2020 (GLOBE NEWSWIRE) -- Chiasma, Inc. (NASDAQ: CHMA), a commercial-stage biopharmaceutical company utilizing its delivery platform technology to develop and commercialize...
5y agoCHMAChiasma to Host an Expert Panel on Acromegaly and the MPOWERED® Phase 3 Trial ResultsGlobeNewswireNEEDHAM, Mass., Nov. 20, 2020 (GLOBE NEWSWIRE) -- Chiasma, Inc. (NASDAQ: CHMA), a commercial-stage biopharmaceutical company utilizing its delivery platform technology to develop and commercialize...
5y agoCHMAChiasma Announces Positive Topline Results from the MPOWERED™ Phase 3 Clinical Trial Comparing MYCAPSSA® (octreotide capsules) to Long Acting Injectables for the Maintenance Treatment of Adults with AcromegalyGlobeNewswire91% of patients on MYCAPSSA maintained IGF-1 response in the 9-month randomized, controlled phase of the non-inferiority trial Company intends to submit a marketing application for MYCAPSSA in the EU...
5y agoCHMAChiasma to Participate in the Jefferies Virtual London Healthcare ConferenceGlobeNewswireNEEDHAM, Mass., Nov. 16, 2020 (GLOBE NEWSWIRE) -- Chiasma, Inc. (NASDAQ: CHMA), a commercial-stage biopharmaceutical company utilizing its delivery platform technology to develop and commercialize...
6y agoCHMAChiasma Reports Third Quarter 2020 Results and Provides MYCAPSSA Launch UpdateGlobeNewswireLaunched MYCAPSSA® in U.S. earlier than expected and recognized first net product revenues in September Well capitalized to support the MYCAPSSA launch On track to announce MPOWERED™ Phase 3 trial...
6y agoCHMAChiasma Reinforces Commitment to People with Acromegaly and Advocacy Organizations on Acromegaly Awareness DayGlobeNewswireNEEDHAM, Mass., Oct. 30, 2020 (GLOBE NEWSWIRE) -- Chiasma, Inc. (NASDAQ: CHMA) today recognizes Acromegaly Awareness Day, which is observed every year on November 1, and reiterates its commitment to...
6y agoCHMAChiasma to Report Third Quarter 2020 Results on November 5GlobeNewswireNEEDHAM, Mass., Oct. 29, 2020 (GLOBE NEWSWIRE) -- Chiasma, Inc. (NASDAQ: CHMA), a commercial stage biopharmaceutical company, today announced that it will host a conference call and live audio...
6y agoCHMAChiasma Announces Planned Transition of Former CEOGlobeNewswireNEEDHAM, Mass., Oct. 01, 2020 (GLOBE NEWSWIRE) -- Chiasma, Inc. (NASDAQ: CHMA), a commercial stage biopharmaceutical company utilizing its delivery platform technology to develop and commercialize...
6y agoCHMAChiasma to Participate in Two September Investor ConferencesGlobeNewswireNEEDHAM, Mass., Sept. 08, 2020 (GLOBE NEWSWIRE) -- Chiasma, Inc. (NASDAQ: CHMA), a commercial stage biopharmaceutical company utilizing its delivery platform technology to develop oral therapies to...
6y agoCHMAChiasma Announces U.S. Commercial Launch and Availability of MYCAPSSA®, the First and Only Oral Somatostatin Analog for Patients with AcromegalyGlobeNewswireNEEDHAM, Mass., Aug. 31, 2020 (GLOBE NEWSWIRE) -- Chiasma, Inc. (NASDAQ: CHMA), a commercial stage biopharmaceutical company utilizing its delivery platform technology to develop oral therapies to...
6y agoCHMAChiasma Announces Publication of Pivotal Data from the Phase 3 CHIASMA OPTIMAL Clinical Trial in the Journal of Clinical Endocrinology & MetabolismGlobeNewswireNEEDHAM, Mass., Aug. 17, 2020 (GLOBE NEWSWIRE) -- Chiasma, Inc. (NASDAQ: CHMA), a commercial stage biopharmaceutical company utilizing its delivery platform technology to develop oral therapies to...
6y agoCHMAChiasma Reports Second Quarter 2020 Results and Significant Progress on Launch PreparednessGlobeNewswireMYCAPSSA® U.S. commercial launch planned for the fourth quarter On track to announce MPOWERED Phase 3 trial topline data in the fourth quarter Company to host conference call today, August...
6y agoCHMAChiasma to Report Second Quarter 2020 Results on August 10GlobeNewswireNEEDHAM, Mass., Aug. 03, 2020 (GLOBE NEWSWIRE) -- Chiasma, Inc. (NASDAQ: CHMA), a commercial stage biopharmaceutical company, today announced that it will host a conference call and live audio...
6y agoCHMAChiasma Announces 48-Week Safety and Efficacy Data from the Open-Label Extension Study of its CHIASMA OPTIMAL Phase 3 Trial Evaluating MYCAPSSA® in Patients with AcromegalyGlobeNewswire-- The mean of the IGF-1 levels for the population of all MYCAPSSA treated patients that completed the 36-week core CHIASMA OPTIMAL trial and continued into the open-label extension (OLE) (n=19) was...
6y agoCHMAChiasma Announces Pricing of a Public Offering of $70 Million of Common Stock and Pre-Funded WarrantsGlobeNewswireNEEDHAM, Mass., July 01, 2020 (GLOBE NEWSWIRE) -- Chiasma, Inc. (NASDAQ: CHMA), a commercial biopharmaceutical company focused on developing and commercializing oral therapies utilizing its...
6y agoCHMAChiasma Announces Proposed Public Offering of Common Stock and Pre-Funded WarrantsGlobeNewswireNEEDHAM, Mass., June 30, 2020 (GLOBE NEWSWIRE) -- Chiasma, Inc. (NASDAQ: CHMA), a commercial biopharmaceutical company focused on developing and commercializing oral therapies utilizing its...
6y agoCHMAChiasma Announces FDA Approval of MYCAPSSA® (Octreotide) Capsules, the First and Only Oral Somatostatin AnalogGlobeNewswireMYCAPSSA is indicated for long-term maintenance treatment in acromegaly patients who have responded to and tolerated treatment with octreotide or lanreotide Conference call and webcast scheduled...
6y agoCHMAChiasma Reports First Quarter 2020 Financial ResultsGlobeNewswireNEEDHAM, Mass., May 07, 2020 (GLOBE NEWSWIRE) -- Chiasma, Inc. (NASDAQ: CHMA), a clinical, late-stage biopharmaceutical company focused on improving the lives of patients who face challenges...
6y agoCHMAChiasma To Report First Quarter Financial Results On May 7, 2020GlobeNewswireNEEDHAM, Mass., April 30, 2020 (GLOBE NEWSWIRE) -- Chiasma, Inc. (NASDAQ: CHMA), a clinical, late-stage biopharmaceutical company focused on improving the lives of patients with rare and serious...
6y agoCHMAChiasma Appoints Anand Varadan as Chief Commercial Officer and Reports Inducement Grant under NASDAQ Listing Rule 5635(c)(4)GlobeNewswireNEEDHAM, Mass., April 22, 2020 (GLOBE NEWSWIRE) -- Chiasma, Inc. (NASDAQ: CHMA), a clinical, late stage biopharmaceutical company focused on improving the lives of patients who face challenges...
6y agoCHMAChiasma, Inc. (CHMA) CEO Raj Kannan on Q4 2019 Results - Earnings Call TranscriptEarnings Call Transcripts
6y agoCHMAChiasma Reports Fourth Quarter and Full Year 2019 Financial ResultsGlobeNewswireMYCAPSSA® PDUFA Date Set for June 26, 2020; U.S. Commercial Launch Planned in Q4’20 First Industry Sponsored U.S. Disease State Registry for Acromegaly Began Enrolling Patients NEEDHAM, Mass.,...
6y agoCHMAChiasma To Report Fourth Quarter and Full Year 2019 Financial Results On March 16, 2020GlobeNewswireNEEDHAM, Mass., March 09, 2020 (GLOBE NEWSWIRE) -- Chiasma, Inc. (NASDAQ: CHMA), a clinical-stage biopharmaceutical company focused on improving the lives of patients with rare and serious chronic...
6y agoCHMAChiasma Provides Corporate Update and Previews 2020 MilestonesGlobeNewswireMYCAPSSA® NDA resubmitted to FDA; PDUFA decision expected mid-2020 MYCAPSSA® U.S. commercial launch planned for the fourth quarter of 2020 Top-line MYCAPSSA® MPOWERED Phase 3 results on track for...